• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2017 - 2020年丹麦模拟医院药品的竞争性招标

Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.

作者信息

Ehlers Lars Holger, Jensen Morten B, Schack Henrik

机构信息

Nordic Institute of Health Economics, Aarhus, Denmark.

Danish Center for Healthcare Improvements, Faculty of Social Sciences and Faculty of Health Sciences, Aalborg University, Aalborg, Denmark.

出版信息

J Pharm Policy Pract. 2022 Oct 22;15(1):69. doi: 10.1186/s40545-022-00464-6.

DOI:10.1186/s40545-022-00464-6
PMID:36273196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9588211/
Abstract

BACKGROUND

Competitive tenders on pharmaceuticals are one of the most effective cost-containment instruments in healthcare systems. Its effectiveness has been demonstrated, among other things, in markets for generic medicine and biosimilars. In Denmark, an internationally unique model for competitive tenders on analogue substitutable pharmaceuticals has been developed and implemented for all public hospitals.

METHODS

We obtained data on all analogue competitive tenders carried out by the Danish Medicines Council from its foundation on January 1, 2017, to October 9, 2020. We calculated univariate descriptive statistics, pairwise correlations and made a multiple regression analysis on tender savings.

RESULTS

Average annual saving on hospital pharmaceutical purchase prices was 44.1% ranging from 0.4% to 92.8% between therapeutic areas and areas of indication. There was a significant positive correlation between tender savings and the number of competitors participating in the tender, and a significant negative correlation between tender savings and the number of days since market authorization.

CONCLUSIONS

This study finds analogue tenders to be similar in effect and mechanism to competitive tenders in markets for generic medicine and biosimilars. It supports the increasing number of empirical findings that competitive tendering has a high potential to generate substantial savings on healthcare budgets.

摘要

背景

药品竞争性招标是医疗保健系统中最有效的成本控制手段之一。其有效性已在仿制药和生物类似药市场等方面得到证明。在丹麦,已为所有公立医院开发并实施了一种国际上独特的可替代药品竞争性招标模式。

方法

我们获取了丹麦药品委员会从2017年1月1日成立至2020年10月9日期间进行的所有可替代药品竞争性招标的数据。我们计算了单变量描述性统计量、成对相关性,并对招标节省金额进行了多元回归分析。

结果

医院药品采购价格的年均节省率为44.1%,不同治疗领域和适应症领域之间的节省率在0.4%至92.8%之间。招标节省金额与参与招标的竞争对手数量之间存在显著正相关,与自市场授权以来的天数之间存在显著负相关。

结论

本研究发现可替代药品招标在效果和机制上与仿制药和生物类似药市场的竞争性招标相似。它支持了越来越多的实证研究结果,即竞争性招标在大幅节省医疗保健预算方面具有很大潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7917/9588211/b278a7f4c4ff/40545_2022_464_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7917/9588211/6254f690d1ee/40545_2022_464_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7917/9588211/b278a7f4c4ff/40545_2022_464_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7917/9588211/6254f690d1ee/40545_2022_464_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7917/9588211/b278a7f4c4ff/40545_2022_464_Fig2_HTML.jpg

相似文献

1
Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.2017 - 2020年丹麦模拟医院药品的竞争性招标
J Pharm Policy Pract. 2022 Oct 22;15(1):69. doi: 10.1186/s40545-022-00464-6.
2
Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.制定具有扩展医疗保健覆盖范围的国家的有效和可持续性的药品招标
Appl Health Econ Health Policy. 2018 Oct;16(5):591-607. doi: 10.1007/s40258-018-0405-7.
3
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.欧洲非专利生物制品和生物类似药招标——迈向更可持续做法的建议
Pharmaceuticals (Basel). 2021 May 24;14(6):499. doi: 10.3390/ph14060499.
4
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.南非 14 年来药品招标对价格和市场集中的影响。
Soc Sci Med. 2019 Jan;220:362-370. doi: 10.1016/j.socscimed.2018.11.029. Epub 2018 Nov 23.
5
The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.欧盟公共采购法规对西班牙招标活动的影响:一项关于阿达木单抗的研究
Front Pharmacol. 2024 Sep 19;15:1447324. doi: 10.3389/fphar.2024.1447324. eCollection 2024.
6
The analogue substitution model: Introducing competition in the absence of generic substitution in Danish hospitals.模拟替代模型:在丹麦医院不存在通用替代的情况下引入竞争。
Health Policy. 2022 Sep;126(9):844-852. doi: 10.1016/j.healthpol.2022.05.018. Epub 2022 Jun 1.
7
Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.意大利生物类似药的区域招标:中标价格的实证分析
Health Policy. 2014 Jun;116(2-3):182-7. doi: 10.1016/j.healthpol.2014.02.011. Epub 2014 Feb 17.
8
Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.西班牙专利过期药品市场的竞争:全国参考定价体系与安达卢西亚地区门诊处方药招标制度的比较。
Health Policy. 2018 Dec;122(12):1310-1315. doi: 10.1016/j.healthpol.2018.10.008. Epub 2018 Oct 12.
9
One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.约旦公共卫生部门药品联合采购的一年期评估。
Clin Ther. 2009 Jun;31(6):1335-44. doi: 10.1016/j.clinthera.2009.05.021.
10
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.绘制依那西普的历程:从专利过期市场的参比药物竞争到生物类似药垄断,追踪波兰的成本动态。
BioDrugs. 2024 Jul;38(4):557-569. doi: 10.1007/s40259-024-00663-4. Epub 2024 Jun 11.

引用本文的文献

1
The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.欧盟公共采购法规对西班牙招标活动的影响:一项关于阿达木单抗的研究
Front Pharmacol. 2024 Sep 19;15:1447324. doi: 10.3389/fphar.2024.1447324. eCollection 2024.
2
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.绘制依那西普的历程:从专利过期市场的参比药物竞争到生物类似药垄断,追踪波兰的成本动态。
BioDrugs. 2024 Jul;38(4):557-569. doi: 10.1007/s40259-024-00663-4. Epub 2024 Jun 11.
3
Tenders for generics and biosimilars: a challenging purchasing policy.

本文引用的文献

1
The analogue substitution model: Introducing competition in the absence of generic substitution in Danish hospitals.模拟替代模型:在丹麦医院不存在通用替代的情况下引入竞争。
Health Policy. 2022 Sep;126(9):844-852. doi: 10.1016/j.healthpol.2022.05.018. Epub 2022 Jun 1.
2
Tendering and biosimilars: what role for value-added services?招标与生物类似药:增值服务扮演何种角色?
J Mark Access Health Policy. 2019 Dec 22;8(1):1705120. doi: 10.1080/20016689.2019.1705120. eCollection 2020.
3
New model for prioritised adoption and use of hospital medicine in Denmark since 2017: Challenges and perspectives.
仿制药和生物类似药的招标:一项具有挑战性的采购政策。
Eur J Health Econ. 2023 Jun;24(4):485-487. doi: 10.1007/s10198-023-01580-z. Epub 2023 Mar 21.
自 2017 年以来丹麦采用和使用医院医学的优先排序新模型:挑战与展望。
Health Policy. 2019 Jul;123(7):606-610. doi: 10.1016/j.healthpol.2019.05.007. Epub 2019 May 16.
4
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.南非 14 年来药品招标对价格和市场集中的影响。
Soc Sci Med. 2019 Jan;220:362-370. doi: 10.1016/j.socscimed.2018.11.029. Epub 2018 Nov 23.
5
Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.西班牙专利过期药品市场的竞争:全国参考定价体系与安达卢西亚地区门诊处方药招标制度的比较。
Health Policy. 2018 Dec;122(12):1310-1315. doi: 10.1016/j.healthpol.2018.10.008. Epub 2018 Oct 12.
6
Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.制定具有扩展医疗保健覆盖范围的国家的有效和可持续性的药品招标
Appl Health Econ Health Policy. 2018 Oct;16(5):591-607. doi: 10.1007/s40258-018-0405-7.
7
Drug tendering: drug supply and shortage implications for the uptake of biosimilars.药品招标:药品供应及短缺对生物类似药采用的影响
Clinicoecon Outcomes Res. 2017 Sep 29;9:573-584. doi: 10.2147/CEOR.S140063. eCollection 2017.
8
Generic Medicine Pricing Policies in Europe: Current Status and Impact.欧洲仿制药定价政策:现状与影响
Pharmaceuticals (Basel). 2010 Mar 5;3(3):471-481. doi: 10.3390/ph3030471.
9
Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.意大利生物类似药的区域招标:中标价格的实证分析
Health Policy. 2014 Jun;116(2-3):182-7. doi: 10.1016/j.healthpol.2014.02.011. Epub 2014 Feb 17.
10
Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?招标采购门诊处方药:从欧洲目前的做法中可以学到什么?
Health Policy. 2011 Jul;101(2):146-52. doi: 10.1016/j.healthpol.2011.03.004. Epub 2011 Apr 21.